Pluristem Of Israel Joins U.S., Europe Trials Of Placenta Cells
This article was originally published in PharmAsia News
Israel's Pluristem Therapeutics says it has qualified as an advisor to the U.S. FDA and the European Medicines Agency for trials of the PLS-PAD cell therapy for blocked arteries
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.